• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.孤儿受体配体人尾加压素II:在人体组织中的受体定位以及与内皮素-1血管收缩反应的比较
Br J Pharmacol. 2000 Oct;131(3):441-6. doi: 10.1038/sj.bjp.0703601.
2
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.人尾加压素II在大鼠、小鼠、犬、猪、狨猴和食蟹猴分离出的血管组织中的不同血管收缩活性。
Br J Pharmacol. 2000 Dec;131(7):1262-74. doi: 10.1038/sj.bjp.0703690.
3
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.人尾加压素II对不同物种离体血管的作用;与其他血管活性药物的比较。
Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):141-9. doi: 10.1007/s00210-001-0503-0. Epub 2001 Nov 20.
4
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.人尿紧张素 II 是一种强效血管收缩剂,也是孤儿受体 GPR14 的激动剂。
Nature. 1999 Sep 16;401(6750):282-6. doi: 10.1038/45809.
5
The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.肽类尾加压素 II 受体配体 GSK248451 在天然哺乳动物组织和重组细胞系统中比低效部分激动剂 SB-710411 和尿紧张素具有更低的内在活性。
Br J Pharmacol. 2006 May;148(2):173-90. doi: 10.1038/sj.bjp.0706716.
6
Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography.
Peptides. 2006 Jun;27(6):1532-7. doi: 10.1016/j.peptides.2005.10.004. Epub 2005 Nov 14.
7
Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.人尾加压素II是大鼠小动脉中的一种内皮依赖性血管舒张剂。
Br J Pharmacol. 2000 Aug;130(8):1865-70. doi: 10.1038/sj.bjp.0703513.
8
Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.人血管系统中平滑肌表达的内皮素ETA和ETB mRNA及受体:以ETA亚型为主。
Br J Pharmacol. 1995 Mar;114(6):1110-6. doi: 10.1111/j.1476-5381.1995.tb13322.x.
9
[125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis.[125I-组氨酸(9)] - 胃饥饿素,一种用于在人和大鼠组织中定位生长激素促分泌素受体的新型放射性配体:动脉粥样硬化时受体的上调。
Br J Pharmacol. 2001 Sep;134(1):143-9. doi: 10.1038/sj.bjp.0704228.
10
Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.来自小鼠和猴子的编码尾加压素 II 肽及其同源 G 蛋白偶联受体的基因的分子和药理学特性
Br J Pharmacol. 2002 May;136(1):9-22. doi: 10.1038/sj.bjp.0704671.

引用本文的文献

1
Current and future strategies for targeting the endothelin pathway in cardiovascular disease.当前和未来针对心血管疾病内皮素途径的靶向策略。
Nat Cardiovasc Res. 2023 Nov;2(11):972-990. doi: 10.1038/s44161-023-00347-2. Epub 2023 Nov 2.
2
Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study.血浆尾加压素II与高血压风险之间的关联:一项前瞻性研究的结果
Int J Hypertens. 2020 Jan 30;2020:3284769. doi: 10.1155/2020/3284769. eCollection 2020.
3
Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels.双相情感障碍中内皮功能障碍的评估:血清内脂素和尾加压素-II水平
Clin Psychopharmacol Neurosci. 2019 May 31;17(2):211-221. doi: 10.9758/cpn.2019.17.2.211.
4
Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?肢端肥大症患者中尿皮质素 II 水平升高是否可预测心血管风险增加?
J Endocrinol Invest. 2019 Feb;42(2):207-215. doi: 10.1007/s40618-018-0905-1. Epub 2018 May 26.
5
The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.神经肽尾加压素II的G蛋白偶联受体UT具有结构和功能趋化因子特征。
Front Endocrinol (Lausanne). 2017 Apr 25;8:76. doi: 10.3389/fendo.2017.00076. eCollection 2017.
6
Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits.中枢给予尾加压素 II 对清醒正常血压家兔压力反射和血压的急性影响。
Front Physiol. 2017 Feb 23;8:110. doi: 10.3389/fphys.2017.00110. eCollection 2017.
7
Plasma urotensin-2 level and Thr21Met but not Ser89Asn polymorphisms of the urotensin-2 gene are associated with migraines.血浆尾加压素-2水平以及尾加压素-2基因的Thr21Met多态性而非Ser89Asn多态性与偏头痛相关。
J Headache Pain. 2016;17:36. doi: 10.1186/s10194-016-0623-z. Epub 2016 Apr 18.
8
Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.Rho/Rho激酶基因多态性与系统性硬化症之间关联的研究。
Rheumatol Int. 2016 Mar;36(3):421-7. doi: 10.1007/s00296-015-3400-4. Epub 2015 Nov 28.
9
The relationship between coronary slow flow phenomenon and urotensin-II: A prospective and controlled study.冠状动脉慢血流现象与尾加压素 -II 的关系:一项前瞻性对照研究。
Anatol J Cardiol. 2015 Jun;15(6):475-9. doi: 10.5152/akd.2014.5481. Epub 2014 Apr 28.
10
A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.勃起功能障碍的一种新治疗方法:尾加压素 II 受体高亲和力激动剂配体
Asian J Androl. 2015 Jan-Feb;17(1):81-5. doi: 10.4103/1008-682X.133322.

本文引用的文献

1
Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.大鼠和人肺动脉对人尾加压素II的收缩反应:内皮因子和大鼠慢性缺氧的影响
Br J Pharmacol. 2000 May;130(2):201-4. doi: 10.1038/sj.bjp.0703314.
2
Urotensin II: fish neuropeptide catches orphan receptor.
Trends Pharmacol Sci. 2000 Mar;21(3):80-2. doi: 10.1016/s0165-6147(00)01449-8.
3
Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.鉴定尾加压素II作为孤儿G蛋白偶联受体GPR14的内源性配体。
Biochem Biophys Res Commun. 1999 Dec 9;266(1):174-8. doi: 10.1006/bbrc.1999.1796.
4
Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction.鉴定参与血管收缩调节的孤儿G蛋白偶联受体的天然配体。
Nat Cell Biol. 1999 Oct;1(6):383-5. doi: 10.1038/14081.
5
Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).
Biochem Biophys Res Commun. 1999 Nov;265(1):123-9. doi: 10.1006/bbrc.1999.1640.
6
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.人尿紧张素 II 是一种强效血管收缩剂,也是孤儿受体 GPR14 的激动剂。
Nature. 1999 Sep 16;401(6750):282-6. doi: 10.1038/45809.
7
Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors.
FEBS Lett. 1999 Aug 20;457(1):28-32. doi: 10.1016/s0014-5793(99)01003-0.
8
Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology.
Trends Pharmacol Sci. 1999 Sep;20(9):370-5. doi: 10.1016/s0165-6147(99)01366-8.
9
Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.青蛙和人类中编码尾加压素II前体的cDNA克隆显示,尾加压素II基因在脊髓运动神经元中强烈表达。
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15803-8. doi: 10.1073/pnas.95.26.15803.
10
Differential distribution of angiotensin AT2 receptors in the normal and failing human heart.血管紧张素AT2受体在正常及衰竭人心脏中的差异分布。
J Pharmacol Exp Ther. 1998 Jan;284(1):323-36.

孤儿受体配体人尾加压素II:在人体组织中的受体定位以及与内皮素-1血管收缩反应的比较

Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

作者信息

Maguire J J, Kuc R E, Davenport A P

机构信息

Clinical Pharmacology Unit, Level 6 Centre for Clinical Investigation, Box 110 Addenbrooke's Hospital, Cambridge, CB2 2QQ.

出版信息

Br J Pharmacol. 2000 Oct;131(3):441-6. doi: 10.1038/sj.bjp.0703601.

DOI:10.1038/sj.bjp.0703601
PMID:11015293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1572358/
Abstract

We have determined the distribution of receptors for human urotensin-II (U-II) in human and rat CNS and peripheral tissues. In rat, [(125)I]-U-II binding density was highest in the abducens nucleus of brainstem (139.6+/-14 amol mm(-2)). Moderate levels were detected in dorsal horn of spinal cord and lower levels in aorta (22. 5+/-6 amol mm(-2)). In human tissues density was highest in skeletal muscle and cerebral cortex ( approximately 30 amol mm(-2)), with lower levels (<15 amol mm(-2)) in kidney cortex and left ventricle. Little binding was identified in atria, conducting system of the heart and lung parenchyma. Receptor density was less in human coronary artery smooth muscle (14.6+/-3 amol mm(-2), n=10) than rat aorta with no significant difference between normal and atherosclerotic vessels. In human skeletal muscle [(125)I]-U-II bound to a single receptor population with K(D)=0.24+/-0.17 nM and B(max)=1.97+/-1.1 fmol mg(-1) protein (n=4). U-II contracted human coronary, mammary and radial arteries, saphenous and umbilical veins with sub-nanomolar EC(50) values. U-II was 50 times more potent in arteries and <10 times more potent in veins than endothelin-1 (ET-1). The maximum response to U-II ( approximately 20% of control KCl) was significantly less than to ET-1 ( approximately 80% KCl). In contrast, in rat aorta, U-II and ET-1 were equipotent with similar maximum responses. This is the first report of high affinity receptors for [(125)I]-U-II in human CNS and peripheral tissues. This peptide produces potent, low efficacy, vasoconstriction in human arteries and veins. These data suggest a potential role for U-II in human physiology.

摘要

我们已经确定了人尿紧张素II(U-II)受体在人和大鼠中枢神经系统及外周组织中的分布。在大鼠中,[(125)I]-U-II结合密度在脑干展神经核中最高(139.6±14 amol mm(-2))。在脊髓背角检测到中等水平,在主动脉中水平较低(22.5±6 amol mm(-2))。在人体组织中,密度在骨骼肌和大脑皮层中最高(约30 amol mm(-2)),在肾皮质和左心室中水平较低(<15 amol mm(-2))。在心房、心脏传导系统和肺实质中几乎没有发现结合。人冠状动脉平滑肌中的受体密度(14.6±3 amol mm(-2),n = 10)低于大鼠主动脉,正常血管和动脉粥样硬化血管之间无显著差异。在人骨骼肌中,[(125)I]-U-II与单一受体群体结合,K(D)=0.24±0.17 nM,B(max)=1.97±1.1 fmol mg(-1)蛋白质(n = 4)。U-II使人类冠状动脉、乳腺动脉、桡动脉、大隐静脉和脐静脉收缩,并具有亚纳摩尔的EC(50)值。U-II在动脉中的效力比内皮素-1(ET-1)高50倍,在静脉中的效力比ET-1高不到10倍。对U-II的最大反应(约为对照氯化钾的20%)明显小于对ET-1的反应(约为80%氯化钾)。相比之下,在大鼠主动脉中,U-II和ET-1效力相当,最大反应相似。这是关于[(125)I]-U-II在人中枢神经系统和外周组织中存在高亲和力受体的首次报道。这种肽在人体动脉和静脉中产生强效、低效的血管收缩作用。这些数据表明U-II在人体生理学中具有潜在作用。